109 related articles for article (PubMed ID: 19500183)
21. Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma.
Lyle PL; Amato CM; Fitzpatrick JE; Robinson WA
Am J Surg Pathol; 2008 Jun; 32(6):858-66. PubMed ID: 18408594
[TBL] [Abstract][Full Text] [Related]
22. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
23. [MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Dereure O
Ann Dermatol Venereol; 2012 Oct; 139(10):691-2. PubMed ID: 23122387
[No Abstract] [Full Text] [Related]
24. Superficial paramucosal clear cell sarcoma of the soft parts resembling melanoma in a 13-year-old boy.
Sidiropoulos M; Busam K; Guitart J; Laskin WB; Wagner AM; Gerami P
J Cutan Pathol; 2013 Feb; 40(2):265-8. PubMed ID: 23228147
[TBL] [Abstract][Full Text] [Related]
25. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
26. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.
Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC
Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439
[No Abstract] [Full Text] [Related]
27. No evidence for c-erbB-2 overexpression in cutaneous melanoma.
Fink-Puches R; Pilarski P; Schmidbauer U; Kerl H; Soyer HP
Anticancer Res; 2001; 21(4A):2793-5. PubMed ID: 11724356
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
30. Clear cell melanoma: a cutaneous clear cell malignancy.
Pletneva MA; Andea A; Palanisamy N; Betz BL; Carskadon S; Wang M; Patel RM; Fullen DR; Harms PW
Arch Pathol Lab Med; 2014 Oct; 138(10):1328-36. PubMed ID: 25268196
[TBL] [Abstract][Full Text] [Related]
31. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
[TBL] [Abstract][Full Text] [Related]
32. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
33. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
34. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
35. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
36. Molecular biology of melanoma.
Swick JM; Maize JC
J Am Acad Dermatol; 2012 Nov; 67(5):1049-54. PubMed ID: 22459362
[TBL] [Abstract][Full Text] [Related]
37. Malignant neurocristic hamartoma: a tumor distinct from conventional melanoma and malignant blue nevus.
Linskey KR; Dias-Santagata D; Nazarian RM; Le LP; Lam Q; Bellucci KS; Robinson-Bostom L; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 Oct; 35(10):1570-7. PubMed ID: 21934481
[TBL] [Abstract][Full Text] [Related]
38. New type of chimeric fusion product between the EWS and ATFI genes in clear cell sarcoma (malignant melanoma of soft parts).
Pellín A; Monteagudo C; López-Ginés C; Carda C; Boix J; Llombart-Bosch A
Genes Chromosomes Cancer; 1998 Dec; 23(4):358-60. PubMed ID: 9824209
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
[TBL] [Abstract][Full Text] [Related]
40. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
